Dyne Therapeutics Ownership | Who Owns Dyne Therapeutics?


OverviewForecastFinancialsChart

Dyne Therapeutics Ownership Summary


Dyne Therapeutics is owned by 116.14% institutional investors, 0.25% insiders. T. rowe price investment management is the largest institutional shareholder, holding 18.73% of DYN shares. T. Rowe Price Small-Cap Stock is the top mutual fund, with 4.24% of its assets in Dyne Therapeutics shares.

DYN Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockDyne Therapeutics116.14%0.25%-16.39%
SectorHealthcare Stocks 50.50%12.33%37.17%
IndustryBiotech Stocks 49.09%12.06%38.85%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
T. rowe price investment management30.91M18.73%$686.56M
Janus henderson group13.65M10.63%$247.43M
Blackrock7.39M9.11%$260.69M
Vanguard group11.22M7.91%$219.38M
Blackrock funding, inc. /de12.40M7.52%$275.50M
Fmr11.21M6.79%$248.91M
State street7.46M4.52%$165.65M
Orbis allan gray7.01M4.25%$155.62M
Atlas venture life science advisors6.80M4.12%$151.03M
Vanguard capital management6.31M3.82%$140.17M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Mpm asset management682.38K19.40%$8.63M
Atlas venture life science advisors6.80M17.14%$151.03M
Fcpm iii services b.v.3.85M11.39%$85.47M
University of wisconsin foundation313.56K5.51%$6.96M
Palo alto investors lp1.65M5.06%$36.59M
Saturn v capital management1.06M3.37%$23.49M
Vivo capital1.56M3.16%$34.59M
Bioimpact capital1.92M2.60%$42.69M
Tcg crossover management4.62M2.46%$102.50M
Logos global management lp2.55M2.44%$56.64M

Top Buyers

HolderShares% AssetsChange
Fmr11.21M0.01%2.30M
Blackrock7.39M0.01%2.00M
Paradigm biocapital advisors lp1.90M0.68%1.90M
Price t rowe associates inc /md/3.94M0.01%1.61M
Vanguard group11.22M0.00%1.46M

Top Sellers

HolderShares% AssetsChange
Ra capital management---9.71M
Holocene advisors, lp---2.35M
Atlas venture life science advisors6.80M17.14%-2.33M
Perceptive advisors2.69M0.90%-1.98M
Jefferies financial group---1.80M

New Positions

HolderShares% AssetsChangeValue
Paradigm biocapital advisors lp1.90M0.68%1.90M$24.02M
Sixth street partners management company1.20M0.00%1.20M$26.70M
Novo960.39K1.24%960.39K$21.33M
Granahan investment management338.56K0.27%338.56K$7.52M
Alyeska investment group245.28K0.01%245.28K$5.45M

Sold Out

HolderChange
Dunhill financial-1.00
Nelson, van denburg & campbell wealth management group-9.00
Creative financial designs inc /adv-10.00
J.safra asset management-11.00
Twin peaks wealth advisors-14.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20262537.20%191,678,1382.03%1160.90%140-2.78%7421.31%
Mar 31, 2026229-4.58%186,215,3694.65%1440.92%139-9.74%607.14%
Dec 31, 202548-77.78%17,667,612-88.66%120.07%33-77.40%8-80.49%
Sep 30, 202556-72.00%16,926,024-86.84%140.12%39-66.95%9-82.69%
Jun 30, 2025198-5.71%128,546,9735.45%1120.92%116-10.08%5215.56%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
T. Rowe Price Small-Cap Stock7.00M4.24%-2.61K
T. Rowe Price US Small-Cap Core Equity7.00M4.24%-7.60K
T. Rowe Price Small-Cap Value4.60M2.78%-19.57K
Vanguard Total Stock Mkt Idx Inv4.47M2.71%-242.06K
Vanguard Morn Total Stk Mkt Idx Investor4.47M2.40%-242.06K
Vanguard US Total Market Shares ETF2.65M2.35%2.40K
T. Rowe Price Instl Small-Cap Stock3.81M2.30%-
State Street® SPDR® S&P® Biotech ETF4.08M2.18%9.36K
Fidelity Growth Compy Commingled Pl S3.99M2.14%195.10K
iShares Russell 2000 ETF3.83M2.05%-67.97K

Recent Insider Transactions


DateNameRoleActivityValue
Aug 13, 2026Rhodes Jason P-Sell$1.67M
Aug 14, 2026Rhodes Jason P-Sell$33.99M
Aug 13, 2026Rhodes Jason P-Sell$7.03M
Aug 13, 2026Rhodes Jason P-Sell$2.47M
Aug 14, 2026Rhodes Jason P-Sell$11.96M

Insider Transactions Trends


DateBuySell
2026 Q3-12
2026 Q2484
2026 Q138
2025 Q4-3
2025 Q315

DYN Ownership FAQ


Who Owns Dyne Therapeutics?

Dyne Therapeutics shareholders are primarily institutional investors at 116.14%, followed by 0.25% insiders and -16.39% retail investors. The average institutional ownership in Dyne Therapeutics's industry, Biotech Stocks , is 49.09%, which Dyne Therapeutics exceeds.

Who owns the most shares of Dyne Therapeutics?

Dyne Therapeutics’s largest shareholders are T. rowe price investment management (30.91M shares, 18.73%), Janus henderson group (13.65M shares, 10.63%), and Blackrock (7.39M shares, 9.11%). Together, they hold 38.47% of Dyne Therapeutics’s total shares outstanding.

Does Blackrock own Dyne Therapeutics?

Yes, BlackRock owns 9.11% of Dyne Therapeutics, totaling 7.39M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 260.69M$. In the last quarter, BlackRock increased its holdings by 2M shares, a 37.05% change.

Who is Dyne Therapeutics’s biggest shareholder by percentage of total assets invested?

Mpm asset management is Dyne Therapeutics’s biggest shareholder by percentage of total assets invested, with 19.40% of its assets in 682.38K Dyne Therapeutics shares, valued at 8.63M$.

Who is the top mutual fund holder of Dyne Therapeutics shares?

T. Rowe Price Small-Cap Stock is the top mutual fund holder of Dyne Therapeutics shares, with 4.24% of its total shares outstanding invested in 7M Dyne Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools